MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering and platform technologies for cell-based therapeutics and bioprocessing applications, has announced its participation in the Virtual Craig-Hallum Capital Group Bioprocessing Conference. The event is scheduled for Thursday, September 19th at 9:30 am ET.
Company management will be presenting at the conference, providing insights into MaxCyte's innovative technologies and market position. For those unable to attend live, a replay of the event will be made available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
This participation underscores MaxCyte's commitment to engaging with the investment community and showcasing its advancements in cell engineering and bioprocessing technologies.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), leader nelle tecnologie di ingegneria cellulare e nelle piattaforme per terapie cellulari e applicazioni di bioprocessing, ha annunciato la sua partecipazione alla Conferenza Virtuale del Craig-Hallum Capital Group sul Bioprocessing. L'evento si terrà giovedì 19 settembre alle 9:30 ET.
La direzione dell'azienda presenterà alla conferenza, fornendo approfondimenti sulle tecnologie innovative di MaxCyte e sulla sua posizione di mercato. Per coloro che non potranno partecipare dal vivo, sarà disponibile una registrazione dell'evento nella sezione 'Eventi' del sito web delle relazioni con gli investitori di MaxCyte all'indirizzo https://investors.maxcyte.com/.
Questa partecipazione sottolinea l'impegno di MaxCyte nel coinvolgere la comunità degli investimenti e nel mostrare i suoi progressi nell'ingegneria cellulare e nelle tecnologie di bioprocessing.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), líder en tecnologías de ingeniería celular y plataformas para terapias basadas en células y aplicaciones de bioprocesamiento, ha anunciado su participación en la Conferencia Virtual del Grupo Capital Craig-Hallum sobre Bioprocesamiento. El evento está programado para el jueves 19 de septiembre a las 9:30 a.m. ET.
La dirección de la empresa presentará en la conferencia, brindando información sobre las innovadoras tecnologías de MaxCyte y su posición en el mercado. Para aquellos que no puedan asistir en vivo, se ofrecerá una repetición del evento en la sección 'Eventos' del sitio web de relaciones con inversores de MaxCyte en https://investors.maxcyte.com/.
Esta participación subraya el compromiso de MaxCyte de interactuar con la comunidad inversora y mostrar sus avances en tecnologías de ingeniería celular y bioprocesamiento.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), 세포 기반 치료 및 바이오 프로세싱 응용 분야를 위한 세포 공학 및 플랫폼 기술의 선두주자는 가상 Craig-Hallum 자본 그룹 바이오 프로세싱 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 9월 19일 목요일 오전 9:30 ET에 예정되어 있습니다.
회사의 경영진이 컨퍼런스에서 발표할 예정이며, MaxCyte의 혁신 기술 및 시장 위치에 대한 통찰력을 제공할 것입니다. 실시간으로 참석할 수 없는 분들을 위해, 이벤트의 재생이 MaxCyte의 투자자 관계 웹사이트 '이벤트' 섹션에서 제공될 예정입니다. 링크: https://investors.maxcyte.com/.
이번 참가로 MaxCyte는 투자 커뮤니티와 소통하고 세포 공학 및 바이오 프로세싱 기술의 발전을 보여주려는 의지를 강조합니다.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), un leader dans les technologies d'ingénierie cellulaire et les plateformes pour les thérapies cellulaires et les applications de bioprocessing, a annoncé sa participation à la Conférence Virtuelle du Groupe Craig-Hallum sur le Bioprocessing. L'événement est prévu pour jeudi 19 septembre à 9h30 ET.
La direction de l'entreprise présentera à la conférence, offrant des perspectives sur les technologies innovantes de MaxCyte et sa position sur le marché. Pour ceux qui ne peuvent pas assister en direct, un enregistrement de l'événement sera disponible dans la section 'Événements' du site web des relations investisseurs de MaxCyte à l'adresse https://investors.maxcyte.com/.
Cette participation souligne l'engagement de MaxCyte à interagir avec la communauté des investisseurs et à mettre en avant ses avancées en ingénierie cellulaire et en technologies de bioprocessing.
MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), ein führendes Unternehmen im Bereich der Zelltechnik und Plattformtechnologien für zellbasierte Therapien und Bioprozessanwendungen, hat seine Teilnahme an der Virtuellen Bioprocessing-Konferenz der Craig-Hallum Capital Group angekündigt. Die Veranstaltung ist für Donnerstag, den 19. September, um 9:30 Uhr ET angesetzt.
Das Management des Unternehmens wird auf der Konferenz präsentieren und Einblicke in die innovativen Technologien und die Marktposition von MaxCyte geben. Für diejenigen, die nicht live teilnehmen können, wird eine Aufzeichnung der Veranstaltung im 'Events'-Bereich der Investor-Relations-Website von MaxCyte unter https://investors.maxcyte.com/ zur Verfügung gestellt.
Die Teilnahme unterstreicht MaxCytes Engagement, mit der Investoren-Community zu interagieren und die Fortschritte in der Zelltechnik und Bioprozess-Technologien zu präsentieren.
- None.
- None.
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the Virtual Craig-Hallum Capital Group Bioprocessing Conference on Thursday, September 19th at 9:30 am ET.
A replay link of the event will be available following the conference on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Anya Bolshem
abolshem@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
FAQ
When is MaxCyte (MXCT) participating in the Craig-Hallum Capital Group Bioprocessing Conference?
Where can I find a replay of MaxCyte's (MXCT) presentation at the Craig-Hallum conference?
What does MaxCyte (MXCT) specialize in?
On which stock exchanges is MaxCyte (MXCT) listed?
